This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wang, B. S. Articles by Mannick, J. A. Search for Related Content PubMed PubMed Citation Articles by Wang, B. S. Articles by Mannick, J. A.

Suppression of Tumor-specific Cell-mediated Cytotoxicity by Immunoregulatory -Globulin and by Immunoregulatory -Globulin-like Peptides from Cancer Patients¹

Departments of Pathology [B. S. W.] and Surgery [J. A. M.], Harvard Medical School, Peter Bent Brigham Hospital, Boston 02115, and Departments of Microbiology [A. M. B.], Biochemistry [R. B. N., K. S.], and Medicine [S. R. C.], Boston University School of Medicine, University Hospital, Boston, Massachusetts 02118

The suppression of tumor-specific cell-mediated cytotoxicity by human immunoregulatory -globulin (IRA), by a peptide fraction derived from IRA, and by IRA-like peptides from the serum of cancer patients was studied in a syngeneic murine tumor-host system. Splenic lymphocytes from tumor-immunized mice were cytotoxic to specific tumor cells in vitro as measured by the [¹²⁵I]iododeoxyuridine release microcytotoxicity assay. However, this effect was significantly depressed if 1.25 to 5 mg of IRA per ml were added to the cultures. Pooled lyophilized normal human serum protein was inactive. IRA peptide and IRA-like peptide fractions from cancer patients were also highly suppressive of cell-mediated cytotoxicity at much lower concentrations (0.05 to 0.5 mg/ml). Control human serum peptide, which failed to inhibit the induction of hemolytic plaque-forming cells in sheep erythrocyte-injected mice, had no effect on cell-mediated cytotoxicity. IRA and IRA-like peptide fractions were not cytotoxic to the effector lymphocytes or to the target cells at the concentrations used.

¹ This work was supported by USPHS Grants CA-21644, CA-15848, CA-15129, CA-12209, and GM-10374.

² To whom requests for reprints should be addressed at the Department of Surgery, Harvard Medical School, Peter Bent Brigham Hospital, 721 Huntington Avenue, Boston, Mass. 02115.

Received 1/20/77. Accepted 5/20/77.